Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about PBYI, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Neratinib (HKI-272) FDA approved Jul 2017 · Nerlynx |
HER2+ Metastatic Breast Cancer (MBC) | Phase 3 · NCT01808573 | Completed |
| Loperamide | Early-stage Breast Cancer | Phase 2 · NCT05252988 | Active not recruiting |
| Cytotoxic Agent-LAT1 Substrate QBS10072S | Glioblastoma | Phase 2 · NCT02977780 | Recruiting |
| Trastuzumab Emtansine | Breast Cancer | Phase 1/2 · NCT02236000 | Completed |
| Fluorouracil | GastroEsophageal Cancer | Phase 2 · NCT06109467 | Active not recruiting |
| Colestipol | Early Stage HER2+ Breast Cancer | Phase 2 · NCT02400476 | Completed |
| Endocrine therapy | Hormone Receptor Positive HER-2 Negative Breast Cancer | Phase 2 · NCT06369285 | Recruiting |
| DNA-PK/TOR Kinase Inhibitor CC-115 | Glioblastoma | Phase 2 · NCT02977780 | Recruiting |
| Alisertib | Small Cell Lung Cancer | Phase 2 · NCT06095505 | Recruiting |
| Diphenoxylate | HER2-positive Breast Cancer | Phase 2 · NCT03094052 | Completed |
| Doxorubicin | Breast Cancer | Phase 2 · NCT01008150 | Completed |
| Osimertinib | Lung Cancer Metastatic | Phase 1 · NCT04085315 | Completed |
| Niraparib at RP2D | Advanced Solid Tumor | Phase 1 · NCT04502602 | Active not recruiting |
| Neratinib Pill | Gastric Cancer | Phase 1 · NCT05274048 | Recruiting |
| Neratinib at RP2D | Advanced Solid Tumor | Phase 1 · NCT04502602 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not PBYI's own candidates): Lapatinib, Capecitabine, Pembrolizumab, Fulvestrant, Letrozole, Oxaliplatin, Paclitaxel, Vinorelbine, Temozolomide, Temsirolimus, Trastuzumab, Abemaciclib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
PBYI holds $108.6M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PBYI files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Alan H Auerbach President and CEO, Director, 10% owner · +502,096 options |
Insider | 8,648,958 | 16.73% | 2026-10-04 |
| American Century Investment Management, | Institution (13G, 5%+) | 2,742,653 | 5.31% | 2026-09-30 |
| Maximo F Nougues Chief Financial Officer · +151,608 options |
Insider | 230,637 | 0.45% | 2026-07-06 |
| Douglas M Hunt Officer · +136,925 options |
Insider | 196,841 | 0.38% | 2026-07-06 |
| Jeffrey Jerome Ludwig Chief Commercial Officer · +66,221 options |
Insider | 156,792 | 0.30% | 2025-02-07 |
| Brian M Stuglik Director |
Insider | 113,858 | 0.22% | 2026-06-11 |
| Allison Dorval Director |
Insider | 90,780 | 0.18% | 2026-06-11 |
| Michael Patrick Miller Director |
Insider | 66,000 | 0.13% | 2026-11-11 |
| Jay M Moyes Director |
Insider | 58,322 | 0.11% | 2026-06-11 |
| Alessandra Cesano Director · +50,000 options |
Insider | 56,700 | 0.11% | 2026-09-14 |
| Troy Edward Wilson Director |
Insider | 55,300 | 0.11% | 2026-09-14 |
| Adrian Senderowicz Director |
Insider | 27,000 | 0.05% | 2026-06-11 |
Share count 51,698,356 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PBYI and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →